Strategic Growth Novuson is actively expanding market reach with a new Executive VP of Business Development appointed in 2025, signaling a deliberate push into broader commercialization and surgical trauma applications. This presents an opportunity to align outreach with their growth initiatives, target health systems and trauma centers, and propose partnership or distribution arrangements to accelerate market adoption.

Clinical Differentiation DTU technology positions Novuson as a fast, precise alternative for vessel sealing and hemostasis, addressing limitations of RF and harmonic methods. Engage clinicians and procurement by highlighting faster procedures, reduced bleeding risk, and potential improvements in intraoperative workflow to drive adoption in operating rooms and trauma settings.

Regulatory & Funding With no commercial availability and recent crowdfunding activity, Novuson is navigating pre-commercial funding and regulatory pathways. Sales strategies can focus on early access programs, partnerships for clinical evaluation, and investor-aligned messaging to secure pilot programs and accelerate revenue generation post-launch.

Strategic Partnerships As a university spinout with unique DTU IP, there is potential to pursue collaborations with major medical device manufacturers or distributors for co-development, licensing, or OEM opportunities. Tailor outreach to highlight complementary capabilities, market access, and speed-to-market advantages for expanding DTU adoption.

Target Market & Channels Customer prospects include hospitals, trauma centers, and surgical centers seeking rapid hemostasis solutions. Focus on enterprise-level procurement, capital equipment budgets, and clinical demand for improved operating room efficiency. Propose pilots, case studies, and training support to reduce adoption barriers and demonstrate return on investment.